Copyright
©The Author(s) 2024.
World J Diabetes. Oct 15, 2024; 15(10): 2135-2146
Published online Oct 15, 2024. doi: 10.4239/wjd.v15.i10.2135
Published online Oct 15, 2024. doi: 10.4239/wjd.v15.i10.2135
Year | CVOT | Intervention | Median follow-up (year) | History of MI (yes, %) | History of HF (yes, %) | Post-baseline GLP-1RA/SGLT-2I (yes, %), intervention/placebo |
2013 | EXAMINE[25] | Alogliptin | 1.5 | N/A | N/A | N/A |
2013 | SAVOR-TIMI 53[26] | Saxagliptin | 2.1 | N/A | N/A | N/A |
2015 | TECOS[27] | Sitagliptin | 3.0 | N/A | N/A | N/A |
2019 2015 | CARMELINA[28] ELIXA[29] | Linagliptin Lixisenatide | 2.2 2.1 | N/A 22 | N/A 22 | N/A N/A |
2016 | SUSTAIN-6[30] | Semaglutide | 2.1 | 32 | 17[31] | 1.5/1.2 |
2016 | LEADER[32] | Liraglutide | 3.8 | 31 | 18[33] | 2.1/2.81 |
2017 | EXSCEL[34] | Exenatide | 3.2 | 32[35] | 16 | 4.4/5.8 |
2018 | HARMONY OUTCOMES[36] | Albiglutide | 1.5 | 47 | 20 | 9.7/10.8 |
2019 | REWIND[37] | Dulaglutide | 5.4 | 16[38] | 9 | 5.2/7.3 |
2019 | PIONEER-6[39] | Semaglutide | 1.3 | 36[31] | 12[31] | 13.5/15.8 |
2021 | AMPLITUDE-O[40] | Efpeglenatide | 1.8 | N/A | 18 | 17.5/21.2 |
2015 | EMPA-REG OUTCOME[41] | Empagliflozin | 3.1 | 47 | 10 | N/A |
2017 | CANVAS[42] | Canagliflozin | 2.4 | 29[43] | 14 | 6.2/7.72 |
2019 | DECLARE-TIMI 58[44] | Dapagliflozin | 4.2 | 21[45] | 10 | 9.5/11.5[19] |
2019 | CREDENCE[46] | Canagliflozin | 2.6 | 10[47] | 15 | 6.5/6.9 |
2020 | VERTIS CV[48] | Ertugliflozin | 3.5 | 48 | 24 | 4.9/5.6 |
Cardiovascular outcome | Covariate | Intervention | HR with 95%CI |
MACE | NA | GLP-1RA vs Placebo | 0.84 (0.77-0.90) |
MACE | 0 | GLP-1RA vs Placebo | 0.89 (0.77-0.99) |
MACE | NA | SGLT-2I vs Placebo | 0.90 (0.82-0.98) |
MACE | 0 | SGLT-2I vs Placebo | 0.95 (0.82-1.08) |
MACE | 1 | Combination vs GLP-1RA | 0.51 (0.16-1.65) |
MACE | 1 | Combination vs SGLT-2I | 0.48 (0.15-1.54) |
Cardiovascular death | NA | GLP-1RA vs Placebo | 0.85 (0.76-0.94) |
Cardiovascular death | 0 | GLP-1RA vs Placebo | 0.88 (0.73-1.07) |
Cardiovascular death | NA | SGLT-2I vs Placebo | 0.90 (0.79-1.02) |
Cardiovascular death | 0 | SGLT-2I vs Placebo | 0.93 (0.76-1.16) |
Cardiovascular death | 1 | Combination vs GLP-1RA | 0.58 (0.08-3.39) |
Cardiovascular death | 1 | Combination vs SGLT-2I | 0.55 (0.07-3.25) |
Fatal and non-fatal MI | NA | GLP-1RA vs Placebo | 0.89 (0.79-0.98) |
Fatal and non-fatal MI | 0 | GLP-1RA vs Placebo | 0.94 (0.79-1.09) |
Fatal and non-fatal MI | NA | SGLT-2I vs Placebo | 0.92 (0.81-1.05) |
Fatal and non-fatal MI | 0 | SGLT-2I vs Placebo | 0.98 (0.81-1.19) |
Fatal and non-fatal MI | 1 | Combination vs GLP-1RA | 0.45 (0.10-2.18) |
Fatal and non-fatal MI | 1 | Combination vs SGLT-2I | 0.44 (0.09-2.10) |
Fatal and non-fatal stroke | NA | GLP-1RA vs Placebo | 0.81 (0.72-0.91) |
Fatal and non-fatal stroke | 0 | GLP-1RA vs Placebo | 0.82 (0.67-1.00) |
Fatal and non-fatal stroke | NA | SGLT-2I vs Placebo | 0.94 (0.82-1.08) |
Fatal and non-fatal stroke | 0 | SGLT-2I vs Placebo | 0.95 (0.75-1.20) |
Fatal and non-fatal stroke | 1 | Combination vs GLP-1RA | 0.86 (0.12-6.23) |
Fatal and non-fatal stroke | 1 | Combination vs SGLT-2I | 0.74 (0.10-5.47) |
Hospitalization for HF | NA | GLP-1RA vs Placebo | 0.90 (0.79-1.02) |
Hospitalization for HF | 0 | GLP-1RA vs Placebo | 0.97 (0.80-1.19) |
Hospitalization for HF | NA | SGLT-2I vs Placebo | 0.68 (0.59-0.79) |
Hospitalization for HF | 0 | SGLT-2I vs Placebo | 0.75 (0.59-0.96) |
Hospitalization for HF | 1 | Combination vs GLP-1RA | 0.26 (0.03-1.88) |
Hospitalization for HF | 1 | Combination vs SGLT-2I | 0.33 (0.04-2.53) |
Cardiovascular outcome | Covariate | Intervention | HR with 95%CI | |
Fatal and non-fatal MI | Prior history of MI | NA | GLP-1RA vs Placebo | 0.91 (0.84-1.01) |
Fatal and non-fatal MI | Prior history of MI | 0 | GLP-1RA vs Placebo | 1.13 (0.85-1.51) |
Fatal and non-fatal MI | Prior history of MI | 1 | GLP-1RA vs Placebo | 0.57 (0.30-1.05) |
Fatal and non-fatal MI | Prior history of MI | NA | SGLT-2I vs Placebo | 0.91 (0.82-1.02) |
Fatal and non-fatal MI | Prior history of MI | 0 | SGLT-2I vs Placebo | 0.84 (0.66-1.07) |
Fatal and non-fatal MI | Prior history of MI | 1 | SGLT-2I vs Placebo | 1.09 (0.66-1.80) |
Cardiovascular death | Prior history of MI | NA | GLP-1RA vs Placebo | 0.88 (0.76-0.99) |
Cardiovascular death | Prior history of MI | 0 | GLP-1RA vs Placebo | 0.93 (0.59-1.48) |
Cardiovascular death | Prior history of MI | 1 | GLP-1RA vs Placebo | 0.74 (0.26-2.01) |
Cardiovascular death | Prior history of MI | NA | SGLT-2I vs Placebo | 0.84 (0.72-0.96) |
Cardiovascular death | Prior history of MI | 0 | SGLT-2I vs Placebo | 0.92 (0.62-1.32) |
Cardiovascular death | Prior history of MI | 1 | SGLT-2I vs Placebo | 0.68 (0.32-1.48) |
Hospitalization for HF | Prior history of HF | NA | GLP-1RA vs Placebo | 0.91 (0.82-1.02) |
Hospitalization for HF | Prior history of HF | 0 | GLP-1RA vs Placebo | 0.93 (0.61-1.42) |
Hospitalization for HF | Prior history of HF | 1 | GLP-1RA vs Placebo | 0.84 (0.20-3.67) |
Hospitalization for HF | Prior history of HF | NA | SGLT-2I vs Placebo | 0.68 (0.60-0.76) |
Hospitalization for HF | Prior history of HF | 0 | SGLT-2I vs Placebo | 0.69 (0.52-0.90) |
Hospitalization for HF | Prior history of HF | 1 | SGLT-2I vs Placebo | 0.62 (0.14-2.80) |
Cardiovascular death | Prior history of HF | NA | GLP-1RA vs Placebo | 0.86 (0.76-0.97) |
Cardiovascular death | Prior history of HF | 0 | GLP-1RA vs Placebo | 0.77 (0.51-1.08) |
Cardiovascular death | Prior history of HF | 1 | GLP-1RA vs Placebo | 1.52 (0.30-10.07) |
Cardiovascular death | Prior history of HF | NA | SGLT-2I vs Placebo | 0.84 (0.73-0.96) |
Cardiovascular death | Prior history of HF | 0 | SGLT-2I vs Placebo | 0.76 (0.52-1.04) |
Cardiovascular death | Prior history of HF | 1 | SGLT-2I vs Placebo | 1.51 (0.29-10.38) |
- Citation: Zhu JJ, Wilding JPH, Gu XS. Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions. World J Diabetes 2024; 15(10): 2135-2146
- URL: https://www.wjgnet.com/1948-9358/full/v15/i10/2135.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i10.2135